Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations

Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations

Cancer patients have an incidence of about 60% kidney disease development and are at elevated risk of acute renal damage. Kidney disease in these patients is frequently associated with nephrotoxicity from the ongoing oncological treatment. New anticancer therapeutic strategies, such as targeted ther...

Full description

Bibliographic Details
Main Authors: Luca Piscitani, Vittorio Sirolli, Lorenzo Di Liberato, Manrico Morroni, Mario Bonomini
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:International Journal of Molecular Sciences
Subjects:
nephrotoxicity
cancer
kidney
VEGF
anti-VEGF agents
immune checkpoint inhibitor
Online Access:https://www.mdpi.com/1422-0067/21/14/4878

Similar Items

Similar Items